

JOINT MEDIA STATEMENT

TGA decision expands choice for abortion and miscarriage care

21 October 2026

Women in Australia now have more time to access early medical abortion, and a new approved option for managing missed miscarriage, after the Therapeutic Goods Administration (TGA) extended the approved use of MS-2 Step (mifepristone and misoprostol) from today.

MS-2 Step is now approved for early medical abortion up to 70 days (10 weeks) of pregnancy, up from 63 days. It is also approved, for the first time, for the medical management of missed miscarriage up to 70 days.

MS Health, the not-for-profit Australian sponsor of MS-2 Step, and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) have welcomed the decision, which follows a rigorous assessment of the evidence by the TGA.

RANZCOG President Dr Nisha Khot said the decision brought the approved use of the medicine into line with the College's guidance.

"This decision aligns the approved use with RANZCOG's Clinical Guideline for Abortion Care, and with practice in comparable countries including the United Kingdom, the United States and Aotearoa New Zealand," Dr Khot said.

A missed miscarriage occurs when a pregnancy has stopped developing but the pregnancy tissue has not passed. Around one in four confirmed pregnancies ends in miscarriage.

"Women experiencing miscarriage should be offered a choice of expectant, medical or surgical management," Dr Khot said. "A registered medical option, with approved prescribing information, gives clinicians clear guidance and gives women greater choice in their care."

MSI Australia and MS Health Chief Executive Officer Aduerty Rao said the extra week would make a real difference for women.

"Early medical abortion is safe and effective, and can be provided through general practice, telehealth and community pharmacy," Ms Rao said. "An extra week gives women more time to get care close to home and means fewer will need surgical care simply because they've passed nine weeks. That matters most for women who already face the biggest barriers, including women in rural and remote areas, women experiencing domestic and family violence, and women on low incomes."

Subsidy through the Pharmaceutical Benefits Scheme (PBS) is a separate process. The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended listing for medical abortion up to 70 days, and will consider the miscarriage indication at its November 2026 meeting.

"PBS listing is what makes this care affordable," Ms Rao said. "Without it, women can pay several hundred dollars rather than the standard co-payment. We look forward to the PBAC's process continuing, so that every woman can access this care."

MS Health and RANZCOG thank the clinicians, researchers and organisations whose evidence and expertise informed this decision, including the SPHERE Women's Sexual and Reproductive Health Coalition and the Early Pregnancy Loss Coalition. Their contribution, often over many years, has made this possible.

ENDS

Support

If this statement raises concerns for you, support after miscarriage is available from Red Nose Grief and Loss on 1300 308 307 (24 hours). Information about pregnancy options is available from MSI Australia on 1300 003 707.

Disclosure

MS Health is the not-for-profit sponsor of MS-2 Step in Australia and a related entity of MSI Australia, a not-for-profit provider of sexual and reproductive healthcare.